Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Analyst Actions: Wachovia, Genentech


From Standard & Poor's Equity ResearchOPPENHEIMER DOWNGRADES WACHOVIA TO UNDERPERFORM FROM PERFORM

Oppenheimer analyst Meredith Whitney downgrades Wachovia (WB) despite the already dramatic decline in the shares and the fact it trading below tangible book value of $13.60, based upon her dramatically diminished EPS outlook.

Whitney notes one of her chief concerns is capital: given the stark disparity in underwriting assumptions between WB and its peers, WB and actual home price declines, she fears that the company will have greatest reckoning with asset re-valuation and/or credit costs.

With shrinking portfolio, she fears WB simply cannot cut costs fast enough to mitigate capital erosion; she believes WB may have reduced its portfolio by $50 billion in the second quarter.

She cuts $1.55 2008 EPS estimate to $1.35 loss, $2.65 2009 EPS estimate to $0.35 loss.

UBS REITERATES BUY ON GENENTECH

UBS analyst Maged Shenouda says Genentech (DNA) posted solid second quarter revenues of $3.24 billion, vs. his $3.23 billion estimate, driven mostly by U.S. Rituxan sales of $651 million vs. his $620 million forecast. Shenouda now sees Rituxan sales of $2.9 billion and $3.1 billion in 2008 and 2009, respectively, as the product reaches another step of growth.

Similarly, the analyst says Avastin beat his $640 million estimate by $10 million, with penetration in the metastatic breast cancer setting reaching 35%, up from 25% before.

The analyst says $0.82 second quarter EPS missed his $0.85 estimate, but excluding $50 million of cost of goods impairments and $33 million of deferred tax liability, he estimates DNA would have posted $0.88. The analyst notes that the company plans to more aggressively buy back stock as a use of excess cash.

Shenouda keeps 92 price target on the stock.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus